News | May 30, 2013

Clinical Data Demonstrates TriGuard TAVI Embolic Protection Device Reduces Brain Lesion Volume

May 30, 2013 — Cerebral function is the essence of quality of life. Its preservation throughout medical procedures is a key component to procedural success and patient care. New scientific data presented at the annual EuroPCR Congress in Paris heightens the spreading understanding and recognition that protecting the brain and preserving brain reserve is an important goal of transcatheter aortic valve replacement (TAVR) and other cardiovascular procedures. 

The first report on the DEFLECT-I clinical trial was presented at EuroPCR, during the Hot-Line - First-in-man in Valvular Heart Disease session by M. Mullen, M.D., the PI of the study. The TriGuard device is designed to minimize the risk of brain damage associated with cardiovascular procedures and was used to filter the embolic material from brain circulation during TAVR. The results demonstrate an impressive reduction of new brain lesion volume during TAVR when performed with the TriGuard Cerebral Protection Device when compared to unprotected procedures (historical data):

  • Maximum single lesion volume in DEFLECT-I was 17 times smaller than the average in the reported literature (0.39 vs. 6.45 cm3), representing a 94 percent reduction.
  • Maximum total lesion volume in DEFLECT-I was 95 percent smaller than the maximum total lesion volume in reported studies (3.94 vs. 70.3 cm3).
  • Average (mean) single lesion volume in DEFLECT-I was 65 percent smaller than the average of reported historical data (0.12 vs. 0.34 cm3), and average total lesion volume was 57 percent smaller than reported average total lesion volume in reported historical data (0.7 vs. 1.64 cm3). 

 

In addition, the brain protection by TriGuard was safe, with no device related adverse events, had no interference with TAVR procedure, and performed optimally covering all three cerebral branches in 87 percent of the cases throughout valve replacement.

TriGuard, the only embolic protection device designed to cover all aortic cerebral branches, is fashioned to accommodate various anatomical variations of the aortic arch.

Keystone Heart's presence at EuroPCR, Europe's largest professional meeting specializing in interventional cardiovascular medicine, was greeted with great interest.  Focus on cardiovascular procedure related brain damage, clinically evident and silent stroke, and potential preventative measures was emphasized in additional sessions, as well as in non-affiliated scientific presentations throughout the course and congress.

Keystone Heart's Scientific Advisory Board Meeting was held adjacent to EuroPCR.  Participating key opinion leaders reached unanimous agreement on a number of issues:

  • Stroke is a devastating adverse event after cardiovascular procedures
  • Systemic therapy is highly unlikely to prevent strokes related to dislodgement of calcified material and valve particles
  • Mechanical protection such as filters or deflection devices should be incorporated into the procedures to protect the brain from ischemic insults
  • DEFLECT-I results demonstrate great promise and value of cerebral protection

"The issue of stroke is one of the key areas of development for enhancing procedural safety in TAVR and other invasive treatments in cardiology," said Jeffrey Moses, M.D., Columbia University in New York. "The preliminary data from the TriGuard MRI study points to this technology as a potential solution to this important issue"

The TriGuard Cerebral Protection Device is an investigational device and not commercially available.

For more information: www.keystoneheart.com

Related Content

Sentinel Cerebral Protection System Reaches 50-Center Adoption Milestone in U.S.
News | Embolic Protection Devices | February 19, 2018
Claret Medical announced that since U.S. Food and Drug Administration (FDA) clearance in June 2017, its Sentinel...
The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices | October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices | September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices | September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices | August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices | April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices | March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices | September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices | September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Overlay Init